NVIV clinical trials will have huge mainstream appeal to the major news media
NVIV will get exposure as clinical trials have huge mainstream appeal to major news media.
I wouldn't be suprised to see share price hit $5 on news media exposure to the potential life-changing treatment. A Sixty NY Times writeup, and Newsweek article would do it.
TV exposure would be helped with showing the monkeys walking. TV wants visuals to go with story and if 60 MInutes wants an interview with Reynolds they will want to show them. That would get a huge amount of public excitement, especialy if Reynolds talks about future trials for chronic SCI.